On the occasion of the 64th annual meeting of the American Society of Hematology (ASH), the world’s largest hematology meeting currently taking place in the United States, MaaT Pharma today presented the complete results from the phase Ib CIMON study carried out for MaaT033:
• The complete results from the phase Ib CIMON study carried out in 21 patients with acute myelogenous leukemia (AML) who received MaaT033, Microbiome Ecosystem TherapyTM (MET) in the form of a capsule administered orally, demonstrated its safety and its ability to increase the richness of the microbiota in terms of microbial species.
• The trial evaluating the tolerated dose of MaaT033 in patients with AML also demonstrated the onset of implantation of beneficial bacterial species.
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]